San Diego sun, sand and science attracts Merck
This article was originally published in Scrip
Executive Summary
With an investment of up to $90 million, Merck is taking advantage of the best of San Diego – the sun, the sand and the scientists – with the creation of an independent nonprofit organization designed to translate basic research into new drug compounds.
You may also be interested in...
Finance Watch: Scripps Research Models A New Way To Fund Translation
Private Company Edition: Scripps Research has a new model for translating academic findings into drugs, including a novel fund for financing that work. Also, in venture capital deals, Oyster Point closes a $93m Series B round and Peloton raises a $150m Series E.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.